Physician profile
Amy M Ladewski
NPI 1083055180
$29,221.85
in general payments reported to CMS, 2019-2025
10 companies · $6,935 in 2025
The $6,935 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $3,245 · 2023: $11K · 2024: $7,814 · 2025: $6,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $3,488 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $2,189 · Honoraria: $1,680 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,395.00 |
| Travel and Lodging | $3,487.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $2,188.97 |
| Honoraria | $1,680.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15,209.97 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,058.51 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $3,087.36 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $3,076.89 | 2023-2025 | Voquezna, Voquezna Dual Pak, Voquezna Triple Pak |
| Novo Nordisk INC | $1,155.00 | 2025 | |
| Gilead Sciences, INC. | $1,110.26 | 2025 | Livdelzi |
| Mahana Therapeutics, INC. | $357.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $91.88 | 2023 | Dupixent |
| Celgene Corporation | $61.27 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ladewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.